Literature DB >> 9808599

Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study.

H A Dakik1, N S Kleiman, J A Farmer, Z X He, J A Wendt, C M Pratt, M S Verani, J J Mahmarian.   

Abstract

BACKGROUND: Patients who have inducible ischemia after acute myocardial infarction (AMI) generally undergo coronary angiography with the intent to revascularize. Whether this approach is superior to intensive treatment with anti-ischemic medications is unknown. METHODS AND
RESULTS: We performed a prospective, randomized pilot study comparing intensive medical therapy with coronary angioplasty (PTCA) for suppression of myocardial ischemia in 44 stable survivors of AMI. Myocardial ischemia was quantified with adenosine 201Tl tomography (SPECT) performed 4.5+/-2.9 days after AMI. All patients at baseline had a large total (>/=20%) and ischemic (>/=10%) left ventricular perfusion defect size (PDS). SPECT was repeated at 43+/-26 days after therapy was optimized. The total stress-induced PDS was comparably reduced with medical therapy (from 38+/-13% to 26+/-16%; P<0.0001) and PTCA (from 35+/-12% to 20+/-16%; P<0.0001). The reduction in ischemic PDS was also similar (P=NS) in both groups. Cardiac events occurred in 7 of 44 patients over 12+/-5 months. Patients who remained clinically stable had a greater reduction in ischemic PDS (-13+/-9%) than those who had a recurrent cardiac event (-5+/-7%; P<0.02). Event-free survival was superior in the 24 patients who had a significant (>/=9%) reduction in PDS (96%) compared with those who did not (65%; P=0.009).
CONCLUSIONS: In this small pilot study, intensive medical therapy and PTCA were comparable at suppressing ischemia in stable patients after AMI. Sequential imaging with adenosine SPECT can track changes in PDS after anti-ischemic therapies and thereby predict subsequent outcome. Corroboration of these preliminary findings in a larger cardiac-event trial is warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808599     DOI: 10.1161/01.cir.98.19.2017

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Cardiac risk defined by stress myocardial perfusion imaging: Impact on physician decision making and cost savings.

Authors:  Kenneth A Brown
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

3.  Monitoring medical management of coronary artery disease: patient selection, optimal management, and potential problems for diagnosis.

Authors:  M D Cerqueira
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

4.  Resolution of perfusion defects with antiischemic medical therapy.

Authors:  H A Dakik; S Alam; N Timani
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

Review 5.  Radionuclide imaging in risk assessment after acute coronary syndromes.

Authors:  J E Udelson; E J Flint
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 6.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 7.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

8.  Patient-centered imaging.

Authors:  E Gordon Depuey; John J Mahmarian; Todd D Miller; Andrew J Einstein; Christopher L Hansen; Thomas A Holly; Edward J Miller; Donna M Polk; L Samuel Wann
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

9.  The role of radionuclide myocardial perfusion imaging for asymptomatic individuals.

Authors:  Robert C Hendel; Brian G Abbott; Timothy M Bateman; Ron Blankstein; Dennis A Calnon; Jeffrey A Leppo; Jamshid Maddahi; Matthew M Schumaecker; Leslee J Shaw; R Parker Ward; David G Wolinsky
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

10.  Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424.

Authors:  Leslee J Shaw; Gary V Heller; Paul Casperson; Romalisa Miranda-Peats; Piotr Slomka; John Friedman; Sean W Hayes; Ronald Schwartz; William S Weintraub; David J Maron; Marcin Dada; Spencer King; Koon Teo; Pamela Hartigan; William E Boden; Robert A O'Rourke; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.